VTAE Insider Trading Activity and SEC Form 4 Filings
VTAE insider trading summary
No open-market insider purchases or sales of Vitae Pharmaceuticals, Inc (VTAE) have been reported on SEC Form 4 in the past 12 months.
Latest VTAE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 14, 2016 | Jeffrey S. Hatfield | Chief Executive Officer | Sell | $1.0M (50,000 @ $20.81) |
| Sep 14, 2016 | Phillip Gross | 10% Owner | Sell | $21.4M (1,025,000 @ $20.85) |
| Sep 14, 2016 | Robert Atchinson | 10% Owner | Sell | $21.4M (1,025,000 @ $20.85) |
| Sep 14, 2016 | Adage Capital Partners, L.P. | 10% Owner | Sell | $21.4M (1,025,000 @ $20.85) |
| Sep 14, 2016 | Adage Capital Partners Gp, L.L.C. | 10% Owner | Sell | $21.4M (1,025,000 @ $20.85) |
| Sep 14, 2016 | Adage Capital Advisors, L.L.C. | 10% Owner | Sell | $21.4M (1,025,000 @ $20.85) |
| Mar 21, 2016 | Donald J Hayden Jr | Director | Sell | $120K (16,130 @ $7.42) |
| Dec 29, 2015 | Donald J Hayden Jr | Director | Sell | $290K (16,130 @ $18.00) |
| Dec 23, 2015 | Jeffrey S. Hatfield | Chief Executive Officer | Sell | $383K (22,524 @ $17.00) |
| Sep 21, 2015 | Donald J Hayden Jr | Director | Sell | $274K (16,130 @ $17.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.